This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.

By studying detailed patient data, researchers aim to find the best ways to treat these patients while reducing short- and long-term side effects. The findings will help refine radiotherapy treatments, ensuring they are as safe and effective as possible. Additionally, the results will provide doctors with better information to help patients understand the potential risks and benefits of their treatment options.

Inclusion Criteria: Complex patients with lung cancer undergoing radiotherapy in one of the following groups;

• Rare histology
• Disease invading vascular structures
• Co-existing interstitial lung disease (ILD)
• Radical re-irradiation
• Oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.

Exclusion Criteria:

• Include patients with stage IV disease who are receiving non-curative intent radiotherapy
• There are no exclusion criteria relating to upper age limit or comorbidities.

Patients over 18 years of age, with stage I, II or III lung cancer undergoing curative-intent radiotherapy at the Christie Hospital.